Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 3/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 7/20 | 0.34 |
| ▸ | NOD2 | Q9HC29 | 7/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 6/20 | 0.33 |
| ▸ | WEE1 | P30291 | 3/20 | 0.32 |
| ▸ | PAK4 | O96013 | 2/20 | 0.32 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.32 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15036021 | 0.79 | RIPK2 (0.40) | SRCFGFR1RIPK2NOD2ACVR1 | |
| SCHEMBL14681945 | 0.78 | PAK1 (0.40) | RIPK2NOD2ACVR1WEE1PAK4 | |
| SCHEMBL14681990 | 0.73 | — | — | |
| SCHEMBL15035095 | 0.73 | PAK3 (0.39) | PKN1PAK1 | |
| SCHEMBL15036005 | 0.72 | WEE1 (0.35) | FGFR1WEE1PAK4PKN1PAK1 | |
| SCHEMBL15036128 | 0.71 | PAK4 (0.47) | WEE1PAK4PKN1PAK1 | |
| SCHEMBL15036120 | 0.71 | RIPK2 (0.39) | SRCFGFR1RIPK2NOD2ACVR1 | |
| SCHEMBL14682028 | 0.70 | CDK4 (0.42) | SRCFGFR1RIPK2NOD2ACVR1 | |
| SCHEMBL15036153 | 0.70 | WEE1 (0.45) | FGFR1RIPK2NOD2ACVR1WEE1 | |
| SCHEMBL15041701 | 0.70 | SRC (0.38) | SRCFGFR1RIPK2NOD2ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252966-A1 | 6-(SULFONYLARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK3 | SRC 222/4885FGFR1 1720/4885RIPK2 870/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | SRC 26/4885FGFR1 1919/4885RIPK2 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.